

#### 招商银行全资附属机构 A Wholly Owned Subsidiary Of China Merchants Bank

# **Tongcheng-Elong (780 HK)**

# **Looking into 2H22E recovery**

Tongcheng-Elong delivered upbeat 1Q22 results, with rev/ adj. net profit +6%/-17% YoY, 4%/12% above consensus. Mgmt. guided 2Q22E rev to decline 40-45% YoY, with adj. net profit at RMB50-100mn. We view the guidance as forgivable, despite topline/ bottom line midpoint 18%/42% below consensus. We believe soft 2Q22E (due to lockdown disruptions) is well priced in recent stock price, and expect 2H22E to see gradual rebound (Sep to reach 2021 level, and 4Q22E to achieve positive growth), with relaxation of travel restrictions after 2Q22 epidemic. Given TC's lower exposure in high-tier cities, we expect TC to deliver above-industry growth, and see faster-than-peers rebound ahead. For the full year, we estimate FY22E topline/bottom line will drop 10%/19% YoY (adj. NPM at 15.4%). We trimmed TC's FY22-24E earnings forecast by 21-27% to reflect COVID-19 resurgence impact, but we believe LT fundamentals remain intact. Adjust TP to HK\$18.

- Upbeat 1Q22 results with solid CNY rebound. 1Q22 rev/adj. net profit +6%/-17% YoY, 4%/12% above consensus, attributable to business recovery in Jan and Feb. By segment, accommodation/ transportation/ others rev +18%/-1%/+20% YoY, vs. our estimates of +12%/-3%/+0% YoY. OPM improved to 8% (vs. 3.5% in 4Q21) thanks to S&M scale-back to cope with epidemic from Mar, despite GPM contraction to 72.5% (vs. 75% in 4Q21). As such, adj. NP recorded RMB245mn (adj. NPM at 14.3%), approaching high end guidance.
- Looking beyond soft 2Q22E on epidemic resurgence. Mgmt guided 2Q22E rev to decline 40-45%, with adj. net profit at RMB50-100mn. 2Q22E would be the worst quarter in 2022, as lockdowns and travel restrictions dampened travel momentum. By segment, we expect accommodation rev to drop 38% YoY in 2Q22E, with lower ADR but higher take rate (>9%, with lighter subsidies and more VAS). We believe transportation would suffer more, and forecast rev to drop 48% YoY in 2Q22E, with stable take rate. Looking ahead, we expect Jul & Aug to see gradual recovery, and Sep to reach 2021 level, with stabilization of COVID cases and lockdown relaxation. 4Q22E might see positive rev growth if the epidemic does not worsen. We forecast FY22E topline/bottom line to decline 10%/19% YoY (adj. NPM at 15.4%). Given TC's lower exposure in high-tier cities, we expect TC to deliver above-industry growth, and see faster-than-peers rebound ahead.
- Maintain BUY. We slightly trimmed TC's FY22-24E earnings forecast by 21-27% to reflect temporary travel restrictions, but expect LT fundamentals to remain intact. Maintain BUY with new TP at HK\$18 (24x FY23E P/E).

### **Earnings Summary**

Lariningo Garriniar y				
(YE 31 Dec)	FY21A	FY22E	FY23E	FY24E
Revenue (RMB mn)	7,538	6,807	8,202	9,536
YoY growth (%)	27.1	-9.7	20.5	16.3
Adj. net income (RMB mn)	1,296	1,049	1,421	1,718
Adj. EPS (RMB)	0.59	0.47	0.64	0.78
YoY growth (%)	35.9	-19.0	35.4	20.9
Consensus EPS (RMB)	NA	0.39	0.67	0.87
P/E (x)	19.8	24.5	18.1	15.0
P/B (x)	1.3	1.2	1.2	1.1
Yield (%)	0.0	0.0	0.0	0.0
ROE (%)	5.0	3.0	4.6	5.6
Net gearing (%)	Net cash	Net cash	Net cash	Net cash

Source: Company data, Bloomberg, CMBIGM estimates

## **BUY (Maintain)**

Target Price HK\$18.0 (Previous TP HK\$20.0) Up/Downside +34.3% Current Price HK\$13.4

#### **China Internet Sector**

## Sophie Huang

(852) 3900 0889 sophiehuang@cmbi.com.hk

#### Eason Xu

(852) 3900 0849 easonxu@cmbi.com.hk

#### Stock Data

Mkt Cap (HK\$ mn)	31,455
Avg 3 mths t/o (HK\$ mn)	105.51
52w High/Low (HK\$)	21.35/ 9.00
Total Issued Shares (mn)	2,218
Source: Bloomberg	

#### **Shareholding Structure**

Tencent	21.47%
Trip.com	20.94%
T Rowe Price	6.02%
Source: Bloombera	

Codroo. Bloomborg

## **Share Performance**

	Absolute	Relative
1-mth	-3.6%	4.2%
3-mth	-17.4%	1.1%
6-mth	-22.2%	-0.8%

Source: Bloomberg

## 12-mth Price Performance



Source: Bloomberg

## Auditor: PwC

## **Related Reports**

- Looking beyond 3M22E epidemic –
   23 March 2022
- 2. Moving into 3Q22 rebound 23 Nov 2021
- 3. China Internet: Embracing a new normal of regulation 8 Nov 2021



Figure	1.	1022	financia	review

RMB mn	1Q20	2Q20	3Q20	4Q20	1Q21	2Q21	3Q21	4Q21	1Q22	QoQ	YoY	Consensus	Diff %
Revenue	1,005	1,200	1,915	1,813	1,614	2,138	1,939	1,846	1,718	-7%	6%	1,656	4%
Operating Profit	(53)	49	293	92	215	335	280	65	138	112%	-36%	136	1%
Net profit	(56)	55	248	80	170	291	226	27	101	277%	-40%	98	3%
Adj. net profit	78	196	373	307	296	398	351	250	245	-2%	-17%	219	12%
Margin (%)													
Gross Margin	65.0%	72.3%	72.0%	73.7%	74.7%	76.4%	73.9%	20.5%	72.5%			74.0%	
Operating Margin	-5.2%	4.1%	15.3%	5.1%	13.3%	15.7%	14.4%	3.5%	8.0%			8.2%	
Adj. net margin	7.8%	16.3%	19.5%	16.9%	18.4%	18.6%	18.1%	13.6%	14.3%			13.2%	
Growth (%)													
Revenue (YoY)	-43.6%	-24.6%	-7.2%	-7.3%	60.6%	78.1%	1.3%	1.8%	6.5%			2.6%	
Revenue (QoQ)	-48.6%	19.4%	59.5%	-5.3%	-11.0%	32.5%	-9.3%	-4.8%	-7.0%			-36.9%	
Operating Profit	-128.1%	-77.5%	-15.6%	-13.4%	-509.0%	580.7%	-4.4%	-29.6%	-36.0%			-42.2%	
Adj. net profit	-82.6%	-43.2%	-11.1%	-7.2%	279.5%	103.0%	-5.6%	-18.5%	-17.3%			-26.0%	

Source: Company data, Bloomberg, CMBIGM estimates

Figure 2: Revenue breakdown

i igaio El Itorollao bioaltao	*****								_		
RMB mn	1Q20	2Q20	3Q20	4Q20	1Q21	2Q21	3Q21	4Q21	1Q22	QoQ	YoY
Total revenue	1,005	1,200	1,915	1,813	1,614	2,138	1,939	1,846	1,718	-7%	6%
Accommodation reservation	229	384	685	647	459	743	645	562	543	-3%	18%
Transportation ticketing	687	726	1,055	1,003	1,023	1,235	1,125	1,075	1,017	-5%	-1%
Others	89	90	175	162	132	160	170	209	158	-25%	20%

Source: Company data, CMBIGM estimates

Figure 3: CMBIGM estimates vs consensus

		CMBIGM			Consensus				
RMB mn, Dec-YE	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E
Revenue	6,807	8,202	9,536	8,368	10,791	12,793	-18.7%	-24.0%	-25.5%
Gross Profit	5,067	6,124	7,123	6,213	8,029	9,528	-18.4%	-23.7%	-25.2%
Operating Profit	542	893	1,191	879	1,606	2,212	-38.4%	-44.4%	-46.2%
Adj. net profit	1,049	1,421	1,718	1,355	1,950	2,395	-22.5%	-27.1%	-28.3%
Adj. EPS (RMB)	0.47	0.64	0.78	0.39	0.67	0.87	21.4%	-4.0%	-11.3%
Gross Margin	74.4%	74.7%	74.7%	74.2%	74.4%	74.5%	+0.2ppts	+0.3ppts	+0.2ppts
Operating Margin	8.0%	10.9%	12.5%	10.5%	14.9%	17.3%	-2.5ppts	-4.0ppts	-4.8ppts
Adj. net margin	15.4%	17.3%	18.0%	16.2%	18.1%	18.7%	-0.8ppts	-0.7ppts	-0.7ppts

Source: CMBIGM estimates, Bloomberg

Figure 4: Earnings revision

	New				Old		Diff (%)			
RMB mn, Dec-YE	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E	
Revenue	6,807	8,202	9,536	8,760	10,539	12104	-22.3%	-22.2%	-21.2%	
Gross Profit	5,067	6,124	7,123	6,563	7,912	9082	-22.8%	-22.6%	-21.6%	
Operating Profit	542	893	1,191	751	1,201	1553	-27.8%	-25.7%	-23.3%	
Adj. net profit	1,049	1,421	1,718	1,446	1,837	2169	-27.4%	-22.6%	-20.8%	
EPS (RMB)	0.47	0.64	0.78	0.65	0.83	0.98	-27.4%	-22.6%	-20.8%	
Gross Margin	74.4%	74.7%	74.7%	74.9%	75.1%	75.0%	-0.5ppts	-0.4ppts	-0.3ppts	
Operating Margin	8.0%	10.9%	12.5%	8.6%	11.4%	12.8%	-0.6ppts	-0.5ppts	-0.3ppts	
Net Margin	15.4%	17.3%	18.0%	16.5%	17.4%	17.9%	-1.1ppts	-0.1ppts	+0.1ppts	

Source: Company data, CMBIGM estimates



# **Financial Summary**

YE 31 Dec (RMB mn)	FY20A	FY21A	FY22E	FY23E	EV24E	Cash flow summary YE 31 Dec (RMB mn)	EA3U V	FY21A	EY22E	EY22E	FY24I
Revenue	5,933	7,538	6,807	8,202	9,536	Profit before tax	398	875	555	906	1,20
Accommodation			•	•	•						•
reservation	1,945	2,409	2,208	2,637	3,314	D&A	379	384	389	394	40
Transportation ticketing	3,471	4,458	3,747	4,457	4,893	Change in working capital	(525)	336	(184)	454	45
Others	516	671	852	1,108	1,330	Others	(188)	148	413	374	32
COGS	(1,697)	(1,890)	(1,740)	(2,078)	(2,414)	Net cash from operating	136	1,904	1,267	2,281	2,58
R&D	(1,246)	, ,	(1,280)	(1,493)	,	Capex & investments	(200)	(200)	(200)	(200)	(200
S&M	(2,131)	, ,	(2,730)	(3,207)	(3,624)	ST investments payments	(247)	(124)	0	0	
Administrative expenses	(522)	(572)	(515)	(532)	(572)	ST investments proceeds	(000)	0	0	0	
Fair value change	65	124	0	0	0	Other	(326)	130 <b>(194)</b>	( <b>200)</b>	( <b>200)</b>	(200
Other income Other gains/(losses).net	99 21	98 69	0	0	0	Net cash from investing	(773)	(194)	(200)	(200)	(200
Operating profit	382	895	<b>542</b>	<b>893</b>	1,191	Equity raised	0	0	0	0	
Operating profit	302	033	342	033	1,131	Change of debts	(77)	0	0	0	
Finance income	23	12	13	13	13	Others	254	(12)	(13)	_	(13
Other income, net	(7)	(33)	0	0	0	Net cash from financing	177	(12)	(13)	(13) <b>(13)</b>	(13
Pre-tax profit	398	875	555	906	1,204	Net cash from illiancing	177	(12)	(13)	(13)	(1,
wax promit	000	0.0	000	555	.,204	Net change in cash	(461)	1,698	1,054	2,068	2,36
Income tax	(72)	(161)	(94)	(154)	(205)	Exchange difference	(6)	0	0	0	_,
Less: Minority interests	2	10	0	0	0	Cash at the beginning of the	2,271	1,804	3,503	4,557	6,62
Less. Millority interests	2	10	U	U	U	year	2,211	1,004	3,303	4,337	
Net profit	328	723	461	752	999	Cash at the end of the year	1,804	3,503	4,557	6,625	8,99
Adj. net profit	954	1,296	1,049	1,421	1,718	Cash at balance sheet	1,804	3,503	4,557	6,625	8,99
Balance sheet						Key ratios					
YE 31 Dec (RMB mn) Non-current assets	FY20A 10,284	FY21A 9,918	FY22E 9,456	FY23E 9,003	FY24E 8,544	YE 31 Dec Sales mix (%)	FY20A	FY21A	FY22E	FY23E	FY24
PP&E	1,226	1,313	1,395	1,472	1,543	Accommodation reservation	32.8	32.0	32.4	32.1	34.
Investments	389	389	389	389	389	Transportation ticketing	58.5	59.1	55.0	54.3	51.
Land use right	0	16	16	16	16	Others	8.7	8.9	12.5	13.5	13.
Intangible assets	7,481	6,961	6,421	5,881	5,341	Total	100.0	100.0	100.0	100.0	100.
Deferred income tax	216	216	216	216	216						
assets Prepayment & other											
receivables	6	57	52	62	72	P&L ratios (%)					
						Gross Margin	71.4	74.9	74.4	74.7	74.
Current assets	8,830	10,154	11,046	13,442	16,128	PreTax Margin	6.7	11.6	8.2	11.0	12.
Account receivable	2,020	1,792	1,630	1,958	2,275	Tax Rate	17.0	17.0	17.0	17.0	17.
Short-term investments	4,913	4,767	4,767	4,767	4,767	Adj. net margin	16.1	17.2	15.4	17.3	18.
Restricted cash	92	92	92	92	92						
Cash and cash equivalent	1,804	3,503	4,557	6,625	8,994	Balance sheet ratios					_
0	4.004	4 000	4 0 4 0	4 000	F 040	Current ratio (x)	2.1	2.3	2.7	2.8	2.
Current liabilities	4,234	4,393	4,042	4,833	5,612	Debtors turnover days	57.3	54.8	54.8	54.8	54.
Borrowings Trade payables	49 2 001	49 2 646	49 2.437	2 909	49 3 3 7 0	Creditors turnover days		2196.2		0.0	511. 0.
Trade payables Other payables and	2,001	2,646	2,437	2,909	3,379	Inventory turnover days	0.0 Net	0.0 Net	0.0 Net	0.0 Net	O.
accruals	2,120	1,621	1,464	1,763	2,050	Net debt / equity ratio (%)	cash	cash	cash	cash	cas
Current income taxes liabilities	64	77	93	111	134						
						Returns (%)					
Non-current liabilities	863	863	863	863	863	ROE	2.4	5.0	3.0	4.6	5.
Borrowings	113	113	113	113	113	ROA	1.7	3.6	2.3	3.5	4.
Deferred income tax liabilities	529	529	529	529	529						
Other payables and accruals	221	221	221	221	221	Per share data					
2001 MAIO						Adj. EPS (RMB)	0.4	0.6	0.5	0.6	0.
Total net assets		15,063	15,844	16,996	18,445	DPS (RMB)	0.0	0.0	0.0	0.0	0.
Non-controlling interest	3	(7)	(7)	(7)	(7)	BVPS (RMB)	6.3	6.8	7.2	7.7	8.
<del>-</del>			15,851								



## **Disclosures & Disclaimers**

## **Analyst Certification**

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

### **CMBIGM Ratings**

BUY : Stock with potential return of over 15% over next 12 months
HOLD : Stock with potential return of +15% to -10% over next 12 months
SELL : Stock with potential loss of over 10% over next 12 months

NOT RATED : Stock is not rated by CMBIGM

OUTPERFORM : Industry expected to outperform the relevant broad market benchmark over next 12 months

MARKET-PERFORM : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months

UNDERPERFORM : Industry expected to underperform the relevant broad market benchmark over next 12 months

### CMB International Global Markets Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

#### **Important Disclosures**

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request.

## For recipients of this document in the United Kingdom

This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.,) of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

#### For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

#### For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.